drug_type
RELEVANT_DRUG
intervention_type
Biological (Antibody-Drug Conjugate)
drug_description
A targeted biologic HER2 dual antibody–drug conjugate (ADC) given IV every 3 weeks; two anti‑HER2 antibodies bind ERBB2 on tumor cells, drive receptor-mediated internalization, and release an intracellular cytotoxic payload to induce tumor cell death; binding may also inhibit HER2 signaling.
nci_thesaurus_concept_id
C200318
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via an enzyme-cleavable linker, to a topoisomerase I (TopoI) inhibitor payload, with potential antineoplastic activity. Upon administration of the anti-HER2/topoisomerase I inhibitor ADC TQB2102, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the TopoI inhibitor inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication which results in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
drug_mesh_term
Injections
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody–drug conjugate in which humanized anti-HER2 antibodies bind ERBB2 on tumor cells, trigger receptor-mediated internalization, and enzymatic cleavage of a linker to release a topoisomerase I inhibitor payload. The released payload inhibits Topo I, blocking DNA replication and causing cell-cycle arrest and apoptosis; antibody binding may also hinder HER2 signaling.
drug_name
TQB2102
nct_id_drug_ref
NCT06452706